The Latest
AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, As Preclinical Candidate (PCC) For Ocular Diseases, Inflammatory Disorders And Aging
Insilico Medicine announces ISM9077 as a potential first-in-class Y Inhibitor for ocular, inflammatory, and aging diseases, advancing AI-driven drug discovery.